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Venous Thromboembolic Disease After
Total Hip and Knee Arthroplasty
By Steven B. Haas, MD, MPH, Robert L. Barrack, MD, Geoffrey Westrich, MD, and Paul F. Lachiewicz, MD
An Instructional Course Lecture, American Academy of Orthopaedic Surgeons
Thromboembolic disease continues to
pose a major threat to patients under-
going total hip and knee arthroplasty.
Despite a great deal of research, there is
still controversy concerning the best
prophylactic regimen. This lecture
outlines the various methods of me-
chanical and pharmacologic prophy-
laxis, describes the pros and cons of
the American College of Chest Physi-
cians (ACCP) guidelines for prevention
of deep venous thrombosis, and pre-
sents the American Academy of Ortho-
paedic Surgeons (AAOS) clinical
guidelines for prevention of symptom-
atic pulmonary embolism in patients




The ideal prophylaxis modality for
the high-risk population of patients
undergoing total hip or knee arthro-
plasty would be clinically effective
without side effects, be practical and
easy to use, require no monitoring,
and be cost-effective. Unfortunately,
this ideal method of prophylaxis does
not exist. The use of anticoagulants
requires constant balancing of the
risk of clots against the risk of
bleeding. Some of these issues can
be overcome with a multimodal
approach, which is the closest to an
‘‘ideal’’ method that is currently
available.
Pharmacologic Prophylaxis
Parenteral heparin, fondaparinux, oral
warfarin, and oral acetylsalicylic acid are
the major existing pharmacologic pro-
phylaxis agents. Desirudin, a hirudin
derivative, has also been approved by
the U.S. Food and Drug Administration
(FDA) for the prevention of venous
thromboembolism. There are many
more medications in various stages of
development, including oral heparin
and direct thrombin inhibitors of fac-
tors IIa, IXa, and Xa such as indrapar-
inux, dabigatran, apixaban, and
rivaroxaban.
Parenteral Heparin
Three different types of parenteral
or low-molecular-weight heparin have
been approved by the FDA. Enoxaparin
(Lovenox) is the most commonly used
and has been approved for patients
undergoing total hip or knee arthroplasty.
In addition, ardeparin (Normiflo) has
been approved for patients undergoing
total knee arthroplasty, and dalteparin
(Fragmin) has been approved for patients
undergoing total hip arthroplasty.
Look for this and other related articles in Instructional Course Lectures,
Volume 58, which will be published by the American Academy of
Orthopaedic Surgeons in February 2009:
 ‘‘Prevention of Symptomatic Pulmonary Embolism in Patients Undergo-
ing Total Hip and Total Knee Arthroplasty: Clinical Guidelines of the
American Academy of Orthopaedic Surgeons,’’ by Paul F. Lachiewicz, MD
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authors, or a member of his or her immediate family, received, in any one year, payments or other benefits of less than $10,000 or a commitment or
agreement to provide such benefits from a commercial entity (DJO Surgical). No commercial entity paid or directed, or agreed to pay or direct, any benefits
to any research fund, foundation, division, center, clinical practice, or other charitable or nonprofit organization with which the authors, or a member of
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Low-molecular-weight heparin
has many advantages, including rapid
antithrombotic action. There is limited
variability in its effects among different
individuals, and prothrombin time and
activated partial thromboplastin time
have little influence. The drug has linear
pharmacokinetics and a half-life of four
and a half hours. No monitoring is
required, allowing more practical
outpatient use, and the drug can be
effective when given every twelve or
twenty-four hours.
The major disadvantages are the
cost and risks of complications and
bleeding. At our institution, low-
molecular-weight heparin therapy costs
$31 per day, compared with $9 per day
for subcutaneous unfractionated hepa-
rin or less than $1 per day for warfarin.
The presence of an epidural catheter is a
contraindication to the use of low-
molecular-weight heparin, as such
catheters increase the possibility of
epidural hematomas and neurological
deficits associated with regional anes-
thesia. The evidence regarding the
greater risk of bleeding complications
is inconclusive, although it is still a
cause for concern. One trial1 demon-
strated a higher prevalence of bleeding
complications, and another2 showed
increased blood loss associated with
low-molecular-weight heparin therapy.
A large randomized prospective study3
showed that the overall prevalences of
symptomatic deep venous thrombosis
and pulmonary embolism in patients
with unilateral primary hip arthroplasty
were similar in a group that received
low-molecular-weight heparin and a
group treated with warfarin, with most
patients having received the study
medication for one to seven days. Just
over 1% (eighteen) of 1516 patients
who received enoxaparin and 0.5%
(eight) of 1495 patients who received
warfarin had major bleeding events. The
prevalence of minor bleeding events was
significantly higher (p = 0.021) in the
patients treated with enoxaparin (140 of
1516, 9.2%) than it was in those treated
with warfarin (106 of 1495, 7.1%).
Francis et al.4 reported that the preva-
lence of bleeding complications at the
operative site and the rate of postoper-
ative transfusions in patients treated
with low-molecular-weight heparin
were significantly higher (p = 0.03 and
p = 0.001, respectively) than the prev-
alences in patients treated with warfarin,
but they did not find any significant
differences between the groups with
respect to the decrease in the hemato-
crit, intraoperative or postoperative
blood loss, or the prevalence of major
bleeding complications.
Oral Warfarin
The pharmacologic agent most com-
monly used for anticoagulation is war-
farin (Coumadin). The widely accepted
and extensively proven efficacy of this
compound and the low risk of bleeding
complications are major benefits. It is
also effective for secondary prophylaxis,
even in patients in whom clots devel-
oped while warfarin was being used as
the primary prophylaxis5. The oral ad-
ministration allows easy continued use
in the outpatient setting.
Limitations of warfarin include the
still-present risk of bleeding complica-
tions and possible inferiority of its effec-
tiveness for primary prevention of
thrombosis compared with that of low-
molecular-weight heparin1. It also re-
quires monitoring to ensure therapeutic
but safe international normalized ratios.
Previous findings6-8 indicate that an in-
ternational normalized ratio of between
2.0 and 2.5 is associated with the lowest
rates of bleeding complications, with
retention of efficacy. The prevalence of
deep venous thrombosis after total knee
arthroplasty in patients treated with
warfarin alone remains as high as 35% to
55%9, indicating that warfarin on its own
is not sufficient for clot prevention. A
number of studies have shown that
warfarin is more effective for prophylaxis
against proximal deep venous thrombo-
sis than it is for prevention of distal deep
venous thrombosis in patients treated
with total hip replacement10-12.
Acetylsalicylic Acid
Acetylsalicylic acid, commonly known
as aspirin, is a simple, inexpensive oral
anticoagulant that does not require
monitoring. It is extremely safe and has
the added benefit of reducing hetero-
topic ossification. Most studies have
shown it to be less effective than both
low-molecular-weight heparin and
warfarin9,13, but it may provide sufficient
prophylaxis against thromboembolic
disease when it is used in combination
with mechanical prophylaxis. Westrich
et al.14 conducted a randomized pro-
spective study comparing treatment
with low-molecular-weight heparin and
a calf mechanical compression device
with treatment with acetylsalicylic acid
and the same device in patients under-
going total knee arthroplasty. The rates
of deep venous thrombosis, as assessed
with ultrasonography, were not signifi-
cantly different between the two groups,
showing that aspirin in combination
with mechanical compression may be as
effective as, and safer than, more ag-
gressive anticoagulant therapy.
Oral Heparin
One promising new pharmacologic
agent that is being developed for anti-
coagulation is oral heparin. The goal of
this new formulation is to attain the
highly effective clot-prevention ability of
parenteral heparin with an easily ad-
ministered oral form of the drug. This
could be achieved by combining unfrac-
tionated heparin and a carrier molecule,
sodium N-(8[2-hydroxybenzoyl]amino)
caprylate, allowing greater gastrointesti-
nal absorption. A recent multicenter,
randomized, double-blind Phase-III
study15 showed that oral heparin de-
creased the prevalence of postoperative
thrombi with a low frequency of bleed-
ing complications in a large population
of patients treated with total hip
arthroplasty.
Other Agents
The other major focus of new research
is the development of compounds that
are able to directly or indirectly inhibit
factors IIa (thrombin), IXa, or Xa in the
coagulation pathway.
Ximelagatran (Exanta and Ex-
arta), an oral direct factor-IIa inhibitor,
initially showed promise, but marketing
and foreign-distribution efforts in the
United States were halted in 2006
because of unacceptable levels of hepa-
totoxicity. Prior to this, conflicting effi-
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cacy results had been shown. Cohen
et al.16 found no overall advantage of
ximelagatran over low-molecular-
weight heparin in patients treated with
hip or knee surgery, but Colwell et al.17
found the efficacy of ximelagatran to be
superior to that of warfarin. Although
ximelagatran had unacceptable serious
side effects, there may be other direct
thrombin inhibitors that can be effective
with fewer side effects.
Recombinant hirudin and its de-
rivative desirudin (Iprivask) are direct
factor-IIa inhibitors in an injectable
form. Hirudin naturally occurs as a
peptide in the salivary glands of me-
dicinal leeches. Early research showed
that the prevalence of deep venous
thrombosis associated with desirudin
was lower than that associated with
enoxaparin18 or unfractionated hepa-
rin19 and that the bleeding risks were
similar18,19. Desirudin is currently ap-
proved for use for the prevention of
thromboembolic disease.
Dabigatran etexilate (Rendix and
Pradaxa), an oral direct factor-IIa in-
hibitor, is currently being assessed in
Phase-III trials. Completed Phase-II
research studies20 comparing dabigatran
etexilate, started one to four hours
postoperatively, with enoxaparin,
started twelve hours preoperatively,
showed that the rates of pulmonary
embolism and deep venous thrombosis
associated with the highest doses of
dabigatran were significantly lower
than those associated with the enox-
aparin (p = 0.0007). The risk of
serious bleeding complications in-
creased in a dose-dependent manner.
The overall efficacy with regard to the
prevention of venous thromboembo-
lism and the risk of bleeding events
were similar to those associated with
enoxaparin.
Fondaparinux (Arixtra) is the first
synthetic inhibitor of factor Xa. It is a
single chemical entity created through a
total chemical synthesis process, which
enables batch-to-batch consistency. It
has a single molecular target within the
coagulation cascade, and there is no
risk of pathogen contamination. It is
administered subcutaneously in daily
doses. Bauer et al.21 carried out a
multicenter, randomized, double-blind
trial comparing fondaparinux (2.5 mg
once daily) with enoxaparin (30 mg
twice daily). The primary outcome was
the development of venous thrombo-
embolism, which was assessed up to
eleven days postoperatively in 724 pa-
tients. The patients who received fon-
daparinux had a significantly lower
prevalence of thromboembolic compli-
cations (p < 0.001), although their risk
of major bleeding was significantly
higher (p = 0.006). Fondaparinux is
FDA-approved and currently available.
Idraparinux is a hypermethylated
fondaparinux derivative. As an indirect
inhibitor of factor Xa, it requires anti-
thrombin as a cofactor. Idraparinux is
administered subcutaneously once a
week. A Phase-II study22 demonstrated a
treatment effect similar to that of war-
farin, with less bleeding than warfarin at
a dose of 2.5 mg but an unacceptable
risk of major bleeding at a dose of
10 mg. Further Phase-III research is in
progress.
Oral factor-Xa inhibitors are also
being developed. One of these, apix-
aban, is currently being evaluated in
Phase-III trials to compare it with
acetylsalicylic acid and warfarin for the
prevention of stroke and systemic em-
bolism23. A previous study on apixaban
therapy in patients treated with total
knee replacement showed a promising
risk-benefit profile when the drug was
given at dosages of 2.5 mg twice a day
and 5 mg once a day 24.
Rivaroxaban (Xarelto) is another
oral factor-Xa inhibitor. It has a rapid
onset, high oral bioavailability, and
predictable pharmacokinetics25. Phase-
II studies showed it to be well tolerated
and effective in the prevention of
thromboembolic disease following or-
thopaedic surgery25-27. A Phase-III study
of patients treated with total knee
replacement showed it to be signifi-
cantly superior to enoxaparin in terms
of efficacy (p = 0.01), with a similar risk
of bleeding25. Currently, four separate
trials are being carried out to assess
rivaroxaban: two involving patients
treated with total hip replacement and
two involving patients treated with total
knee replacement.
Mechanical Prophylaxis
Mechanical devices help to prevent
venous thromboembolic disease by in-
creasing fibrinolysis and decreasing sta-
sis with accelerated venous emptying.
Their efficacy has been proven in the
fields of general surgery and neurosur-
gery as well as orthopaedic surgery. Foot
pumps, calf pumps, and calf/thigh
pumps are the three major types of
mechanical prophylaxis devices. The
type of pneumatic compression also
varies. It may be standard pneumatic
compression, sequential, or rapid infla-
tion. Although these compression de-
vices are associated with extremely low
complication rates, compliance issues
may decrease their effectiveness. Re-
search on these devices has been less
extensive than that on pharmacologic
agents, but a number of studies have
been conducted to compare the pro-
phylaxis efficacy and compliance rates
associated with different device types
and compression types.
In a randomized prospective
study by Westrich and Sculco28, the
combination of pneumatic plantar
compression and acetylsalicylic acid was
compared with acetylsalicylic acid alone
for prophylaxis for patients treated with
total knee replacement. The trial in-
cluded 164 knees in 121 patients
(seventy-eight treated with a unilateral
total knee arthroplasty and forty-three,
with a bilateral total knee arthroplasty).
The rate of deep venous thrombosis in
the group treated with compression and
acetylsalicylic acid (27%, twenty-two of
eighty-one) was significantly lower (p <
0.001) than that in the group treated
with acetylsalicylic acid alone (59%,
forty-nine of eighty-three). There was
also a direct relationship between com-
pliance with use of the mechanical
compression device and the efficacy of
the device with regard to prevention of
deep venous thrombosis, as assessed
with venography (or, if a venogram was
unattainable or contraindicated, venous
Doppler ultrasound). In another recent
randomized prospective study29, Ryan
et al. compared the efficacy of an im-
pulse mechanical compression device
with that of prophylactic stockings for
prevention of pelvic and proximal deep
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venous thrombosis, as assessed with
magnetic resonance venography, in 100
patients treated with total hip replace-
ment. The mechanical compression led
to a significantly lower rate of deep
venous thrombosis (8%, four of fifty)
compared with that associated with the
use of prophylactic stockings (22%,
eleven of fifty) (p < 0.05).
In 2004, Lachiewicz et al.30 con-
ducted a randomized prospective study
of 423 patients who had a total of 472
knee replacements. The patients were
randomized to treatment with either a
rapid-inflation asymmetrical com-
pression device or a sequential cir-
cumferential compression device. The
prevalence of thrombi in the patients
treated with the rapid-inflation asym-
metrical compression device (6.9%,
sixteen of 206) was significantly lower
(p = 0.007) than that in the patients
treated with the sequential circumfer-
ential compression device (15.0%,
thirty-six of 217).
The hemodynamics in patients
treated with total hip or total knee
arthroplasty were examined in two
other studies31,32. One31, in patients who
underwent total knee replacement,
tested three calf-and-thigh pump de-
signs, two foot pump designs, one foot-
and-calf pump design, and one calf
pump design. The greatest increase in
venous volume and velocity (below the
saphenous vein) was found in the
patients treated with a device that
incorporated rapid calf compression. In
the other study32, involving patients who
underwent total hip replacement, three
calf-and-thigh pump designs, two foot
pump designs, one foot-and-calf pump
design, and one calf pump design were
tested. The greatest increase in peak
venous velocity occurred with pulsatile
calf and calf-and-foot pneumatic com-
pression with a rapid inflation time. The
final key finding was that, because of
compliance issues, simple and easy-
to-apply efficacious devices have the
greatest chance of success.
A prospective study33 of 100
patients showed that the rate of com-
pliance with the use of a foot-pump
pneumatic compression device (Plexi-
Pulse) after total knee arthroplasty was
90.1%. Patients found the device to be
relatively comfortable and easy to apply
and remove, and nurses rated this
device highly in comparison with other
pneumatic compression devices. Be-
cause a device is effective only when it is
used as directed, it is important to
consider ease of use and likelihood of
staff and patient compliance, not just
‘‘ideal’’ use, when evaluating different
types of mechanical compression
devices.
Inferior Vena Cava Filters
Inferior vena cava filters do not prevent
deep venous thrombosis, but they can
prevent pulmonary embolization. They
are often inserted in patients with a
history of venous thromboembolic dis-
ease and those with substantial trau-
matic injuries before other prophylaxis
methods can be initiated. Inferior vena
cava filters are recommended if phar-
macologic anticoagulant therapy is
clearly contraindicated or if the patient
has had thromboembolic complications
despite adequate anticoagulation in the
past34. The cost of these filters is sub-
stantial, and the application is an inva-
sive procedure that requires the use of
contrast agents, exposing the patient to
a risk of complications35. A promising
development has been the introduction
of retrievable inferior vena cava filters,
which may decrease the risks of com-
plications associated with permanent
filter placement. Early data have shown
that retrievable filters are effective in
preventing pulmonary embolism, with a
low rate of insertion-related complica-
tions36,37. These filters can be left in place
permanently or removed when they are
no longer needed; however, because of
clots lodged in the filter or difficulty
with capturing the filter, planned re-
moval may not always be possible38.
Multifactorial Approach
A review39 of fifty studies involving a
total of 10,929 patients who had un-
dergone total hip replacement revealed
deep venous thrombosis rates of 48% in
patients treated with a placebo, 31% in
those treated with acetylsalicylic acid,
23% in those treated with warfarin, 21%
in those treated with pneumatic com-
pression, and 18% in those treated with
low-molecular-weight heparin. The
lowest rate of distal deep venous
thrombosis was in the pneumatic com-
pression group, and this rate was sig-
nificantly lower than that in the aspirin
group and the warfarin group (p =
0.0007 and p = 0.0001, respectively).
Proximal deep venous thrombosis was
significantly less common in the warfa-
rin group and the low-molecular-weight
heparin group (p = 0.0004 and p =
0.0059, respectively) than it was in the
pneumatic compression group. The over-
all prevalence of symptomatic pulmonary
embolism was <1% in the low-molecular-
weight heparin, warfarin, and pneumatic
compression groups, but the aspirin
group had a significantly higher rate of
symptomatic pulmonary embolism
than the warfarin and low-molecular-
weight heparin groups (p < 0.0083).
In another extensive review arti-
cle40, the authors examined twenty-
three trials that included 6001 patients
treated with total knee replacement.
They found a deep venous thrombosis
rate of 53% in association with aspirin
therapy, 45% in association with war-
farin, 29% in association with low-
molecular-weight heparin, and 17% in
association with pneumatic compres-
sion. This study did not include a
placebo group, and the rates of proximal
and distal deep venous thrombosis were
not examined separately. Patients who
received low-molecular-weight heparin
or pneumatic compression were signif-
icantly less likely to have a deep venous
thrombosis than were patients who
received aspirin (p < 0.0001) or warfa-
rin (p < 0.0001). The patients treated
with aspirin had a significantly higher
rate of pulmonary embolism than the
patients who received any other means
of prophylaxis (p < 0.05). In both of the
meta-analyses, the rates of deep venous
thrombosis with the use of each singular
modality were substantially higher than
rates that have been associated with a
combination of chemical and mechan-
ical means. Trials of the use of com-
pression devices in conjunction with
postoperative aspirin therapy have
shown this combination to be as effec-
tive as low-molecular-weight heparin
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for the prevention of proximal and
distal deep venous thrombosis, with a
decreased risk of major bleeding
complications9,39,40.
Our institution uses and advo-
cates a multifactorial approach to pre-
vent venous thromboembolism that
has been validated by extensive re-
search14,35,40-42. The protocol includes a
combination of preoperative, intraop-
erative, and postoperative prophylaxis
techniques. Preoperative assessment in-
volves a full medical evaluation with
special attention paid to coagulation
risk factors such as a current malignant
tumor, a history of pulmonary embo-
lism or deep venous thrombosis, estro-
gen therapy, oral contraceptive use, and
tobacco use. Patients must discontinue
the use of any procoagulant medication
prior to admission. Autologous blood
donation is also encouraged because it
has been proven to significantly reduce
the prevalence of deep venous throm-
bosis after total hip and total knee
arthroplasty (p = 0.003 and p < 0.01,
respectively)43,44.
There are intraoperative tech-
niques that may reduce the risk of
thromboembolic complications. Using
regional anesthesia decreases blood loss
and the rate of deep venous thrombosis,
and intraoperative pneumatic com-
pression decreases venous stasis and the
risk of clotting45-47. A surgical duration
of less than seventy minutes also de-
creased the rate of deep venous throm-
bosis in patients treated with total knee
arthroplasty48. A single intraoperative
dose of unfractionated heparin may
decrease the rate of deep venous
thrombosis after total hip arthroplasty,
but the data with regard to total knee
arthroplasty are less conclusive9,49.
The standard inpatient postoper-
ative prophylaxis includes intermittent
pneumatic compression and pharma-
cologic prophylaxis (usually warfarin, or
aspirin if warfarin is contraindicated).
Furthermore, it is important for pro-
phylaxis to continue following discharge
from the hospital and for the patient
to be aware of the symptoms of ve-
nous thromboembolism postdischarge.
Pellegrini et al.5 found that secondary
prophylaxis with extended warfarin
therapy reduced the rates of readmis-
sion for the treatment of pulmonary
embolism, deep venous thrombosis, or
bleeding after total knee replacement,
and they recommended that patients
continue to take warfarin following
discharge. Another recent study13
showed that, even if screening tests
reveal negative findings, discharging
patients without continuing prophylaxis
after a total hip or knee arthroplasty is
not cost-effective.
In a large study from our institu-
tion, Gonza´lez Della Valle et al.41 found
that a multimodal approach of preop-
erative and intraoperative measures
combined with pneumatic compres-
sion, knee-high elastic stockings, early
mobilization, and chemoprophylaxis
with acetylsalicylic acid (83% of pa-
tients) or warfarin (17%) for four to six
weeks following total hip arthroplasty
was safe and efficacious. The study
included 1947 consecutive patients
(2032 total hip arthroplasties) who were
observed prospectively for three
months. The first 171 patients had a
6.4% prevalence of asymptomatic deep
venous thrombosis as assessed with
ultrasound, and the other 1776 patients
had a 2.5% prevalence of clinical deep
venous thrombosis. Nonfatal symptom-
atic pulmonary embolism occurred in
0.6% (twelve) of the 1947 patients. The
low rates of thromboembolic compli-
cations in this high-risk population are
evidence that routine anticoagulation
with chemoprophylactic agents that
may increase the risk of bleeding, such
as low-molecular-weight heparin, is
unnecessary. The authors of a review of
prophylaxis following total knee ar-
throplasty concurred35, finding that ‘‘no
one method of prophylaxis has been
shown to be ideal and there is little
doubt that more than one modality
focusing on both mechanical and
chemical means of prevention need to
be employed.’’
Pros and Cons of the ACCP
Guidelines for Prophylaxis Against
Deep Venous Thrombosis After
Total Joint Replacement
In 2004, the recommendations of the
Seventh ACCP Conference on Antith-
rombotic and Thrombolytic Therapy
for prophylaxis against deep venous
thrombosis were published50. These
recommendations were based on a
systematic review of the literature by
experts in the field, with use of strict,
well-defined criteria for inclusion of
studies. Since the recommendations of
the ACCP are frequently utilized as a
standard, it is important to understand
the methodology as well as the advan-
tages and disadvantages of these guide-
lines51. The criteria for inclusion of
studies that form the basis of the
recommendations included a defined
patient population that was identified as
belonging to the group at risk, a sample
size of at least ten patients in each
group, and an identifiable end point
normally consisting of the prevalence of
deep venous thrombosis as demon-
strated by contrast venography. Only
randomized clinical trials were assessed
for the determination of prophylaxis
efficacy. Final recommendations were
based on comments from five to ten
external reviewers. The rationale for
prophylaxis for hospitalized patients
was based on the high prevalence of
venous thromboembolism, the adverse
consequence of sequelae of deep
venous thrombosis, and the efficacy and
effectiveness of thromboprophylaxis.
Patients undergoing total joint replace-
ment were considered to be either at
high risk or at the highest risk depend-
ing on their age, the presence of addi-
tional risk factors, and the high-risk
nature of arthroplasty surgery.
Additional rationales for routine
thromboprophylaxis for patients un-
dergoing total joint arthroplasty were
that most postoperative deep venous
thrombi and pulmonary emboli are
clinically silent, it is difficult to predict
whether symptomatic deep venous
thrombosis or pulmonary embolism
will develop in a particular patient, and
identifying ‘‘at risk’’ patients with either
physical examination or screening mo-
dalities has proven to be generally
ineffective. Also, the cost of diagnosing
and treating the sequelae of venous
thromboembolic disease is substantial.
In addition to the risk and cost of
treating a disease that could have been
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prevented, there is an increased future
risk of recurrent disease and its sequelae
such as chronic post-thrombotic syn-
drome. The underlying assumptions
regarding the effectiveness of thrombo-
prophylaxis include evidence that pro-
phylaxis is very effective in lowering
the prevalence of deep venous throm-
bosis, that prophylaxis can prevent both
symptomatic pulmonary embolism
and fatal pulmonary embolism, and
that prophylaxis against deep venous
thrombosis is cost-effective. Also un-
derlying these recommendations are the
facts that many cases of symptomatic
venous thromboembolic disease occur
after discharge, failure to prevent ve-
nous thromboembolic disease results in
therapeutic anticoagulation with addi-
tional substantial risks, and venous
thrombi can result in a number of
sequelae that are frequently overlooked.
These sequelae include post-thrombotic
syndrome, which can cause leg swelling,
dermatitis, and ulcers; venous insuffi-
ciency; and persistent venous occlusion.
The clinical diagnosis of venous
thromboembolic disease is unreliable,
and routine screening of asymptomatic
patients has proven to be not cost-
effective. There is a strong case, there-
fore, for primary prophylaxis on a
routine basis. Of all practices reviewed
by the Agency for Healthcare Research
and Quality (AHRQ) in terms of their
ability to reduce adverse events while
decreasing overall costs, prophylaxis
against deep venous thrombosis has
received the highest safety rating.
The end point selected for the
clinical trials on thromboprophylaxis
by the ACCP was venographically
proven deep venous thrombosis. While
it is recognized that most asymptom-
atic deep venous thrombi are not
clinically relevant, there is allegedly a
strong concordance between the ‘‘sur-
rogate’’ outcome of asymptomatic
deep venous thrombosis and clinically
important deep venous thrombosis,
with a ratio estimated to range from five
to one to ten to one. The use of a
decrease in mortality or the rate of
symptomatic pulmonary embolism
alone as an end point has been termed
‘‘problematic.’’50
On the basis of these underlying
assumptions and rigorous methodol-
ogy, evidence-based guidelines, rated as
either Grade 1 (defined as strong and
indicative of benefits that outweigh risk,
burden, and cost) or Grade 2 (defined as
being less certain with regard to the
magnitude of benefits, risks, and costs),
were released. Grade-1 recommenda-
tions were subdivided into Grade-1A
recommendations, which are based
on randomized clinical trials with con-
sistent results that provide unbiased
recommendations; Grade-1B recom-
mendations, which are based on ran-
domized clinical trials with inconsistent
results or with major methodological
weaknesses; and Grade-1C recommen-
dations, which are based on observa-
tional studies or on generalization from
one group of patients included in ran-
domized clinical trials to a different, but
somewhat similar, group of patients
who did not participate in those trials52.
The Grade-1A recommendations for
prophylaxis for hip replacement in-
cluded administration of warfarin with
a target international normalized ratio
TABLE I Comparison of Efficacy and Complications with an ACCP Grade-1A Protocol with Previous Results with a Non-ACCP





Coumadin (Warfarin) P Value
Major complications 11/129 (9%) 15/705 (2.1%) <0.001
Symptomatic deep venous thrombosis 9/129 (7%) 11/705 (1.6%) <0.001
Pulmonary embolism 2/129 (1.6%) 1/705 (0.1%) <0.01
Hematoma/reoperation 3/129 (2.3%) 2/705 (0.3%) <0.01
Local wound problems 8/129 (6.2%) 4/705 (0.6%) <0.001
Heparin-induced thrombocytopenia 1/129 (0.8%)
TABLE II Results of Lower-Dose Warfarin Protocols for Patients Treated with Joint Arthroplasty
Study No. of Cases Target Pulmonary Embolism Death
Vresilovic et al.102 852 Prothrombin time, 1.2-1.4 · control 6 (0.7%) 0
Paiement et al.103 268 Prothrombin time, 1.25-1.5 · control 2 (0.7%) 0
Lieberman et al.104 1099 Prothrombin time, 14-17 sec 12 (1.1%) 1 (0.09%)
Pellegrini et al.79 1972 International normalized ratio, 2.0 14 (0.7%) 3 (0.15%)
Pellegrini et al.5 1321 International normalized ratio, 2.0 9 (0.7%) 2 (0.15%)
Keeney et al.105 705 International normalized ratio, 2-2.5 5 (0.7%) 0
Total 6217 48 (0.77%) 6 (0.1%)
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of 2.5 (range, 2 to 3), low-molecular-
weight heparin, or fondaparinux, for a
minimum of ten days. The recommen-
dations were the same for knee re-
placement but included pneumatic
compression devices as a Grade-1B
recommendation. There was a Grade-
1A recommendation against the use of
aspirin alone following elective hip or
knee arthroplasty. A prolonged course
of treatment, for four to five weeks,
was recommended for patients at
highest risk.
In addition to the rigorous, well-
described methodology underlying the
ACCP guidelines, an advantage of these
recommendations is that they meet
the criteria of virtually every oversight
group, including hospitals, health
maintenance organizations, and insur-
ance companies, and therefore follow-
ing them minimizes medicolegal
exposure. The ACCP Grade-1A recom-
mendations also meet requirements of
state and federal programs, including
the Surgical Care Improvement
Project (SCIP) and the Center for
Medicare and Medicaid Services Pay-
for-Performance program (CMS P4P
program) initiative. The SCIP has a goal
of reducing surgical complications by
25% by 201053,54. Four areas have been
targeted, one of which is minimizing
venous thromboembolism. The P4P
program was implemented by the Tax
Relief and Health Care Act of 200655. In
2007, the Physician Quality Reporting
Initiative (PQRI) identified numerous
health-quality measures, including ve-
nous thromboembolism prophylaxis for
all patients for whom it is indicated.
Reporting that three performance mea-
sures were met for 80% of eligible
patients qualified physicians for a 1.5%
bonus while failure to report or comply
in the future will in all likelihood result
in a decreased reimbursement56. While
the ACCP recommendations for pro-
phylaxis against deep venous thrombo-
sis after hip and knee arthroplasty meet
the requirements of the federal pro-
grams, following these recommenda-
tions is not necessary to satisfactorily
meet the requirements of those pro-
grams. According to the manual for
National Hospital Quality Measures, use
of low-molecular-weight heparin, factor-
Xa inhibitor, or warfarin meets the
requirement for both total hip replace-
ment and total knee replacement57. In
addition, pneumatic compression de-
vices meet the requirement for elective
total knee arthroplasty. Of note is the
fact that neither the dose nor the
duration of pharmacologic prophylaxis
is specified; this is especially relevant for
warfarin, for which lower-dose proto-
cols are often embraced by orthopaedic
surgeons and shorter durations of pro-
phylaxis have occasionally been used
successfully as well. Aspirin alone is not
recommended for prophylaxis against
deep venous thrombosis.
Potential problems with following
Grade-1A protocols have been noted in
recent studies. Reviews of the available
literature, particularly studies related to
hip and knee arthroplasty, have resulted
in differing conclusions. One major
issue is whether the prevalence of deep
venous thrombosis should be used as a
surrogate marker for effectiveness since
deep venous thrombosis does not cor-
relate with symptomatic pulmonary
embolism or death rates following hip
and knee arthroplasty. Deep venous
thrombosis is two to three times more
common after knee replacement than it
is after hip replacement, but the prev-
alence of pulmonary embolism follow-
ing total knee arthroplasty is equivalent
or reduced compared with that after
total hip arthroplasty58. Also of crucial
importance is the observation, sup-
ported by a number of clinical studies,
that the more effective reduction of
deep venous thrombosis achieved with
the aggressive use of chemoprophylactic
agents leads to a higher risk of bleeding
and subsequent morbidity. One recent
study showed that converting to an
ACCP Grade-1A protocol actually sub-
stantially increased complications and
decreased efficacy compared with the
outcomes associated with a previously
utilized protocol that did not meet any
of the criteria set forth by the ACCP59.
Prior to 2004, 705 patients were treated
with a short course (seven days) of low-
dose Coumadin (warfarin), with a tar-
get international normalized ratio 2 to
2.5, and routine predischarge ultra-
sound screening. This course was
shorter than the ten-day minimum
recommended by the ACCP, the target
international normalized ratio was
lower than that recommended by the
ACCP, and the use of routine screening
was in disagreement with a Grade-1A
ACCP negative recommendation. In
spite of this, the efficacy of the pre-2004
protocol was high, with no deaths and
only one symptomatic pulmonary em-
bolism (0.1%). Patient acceptance of the
protocol was high, with most of them
receiving most or all of their prophy-
lactic treatment while they were in the
hospital, and the cost of the protocol to
the patient was usually zero. On the
basis of the ACCP recommendations,
the protocol at the institution was
changed in conjunction with an insti-
tutional review board-approved pro-
spective study in which a ten-day course
of low-molecular-weight heparin was
TABLE III Levels of Evidence
I High-quality randomized trial
II Cohort study (good control)
III Case-control study
IV Uncontrolled case series
V Expert opinion
TABLE IV Strength of Recommendation
A Good evidence: Level-I studies with consistent findings (adequate
quality and applicability)
B Fair evidence: Level-II or III studies with consistent findings (adequate
quality and applicability)
C Poor evidence: Level-IV or V studies with consistent findings
D Insufficient or conflicting evidence not allowing a recommendation
2770
TH E J O U R N A L O F B O N E & JO I N T SU R G E RY d J B J S . O R G
VO LU M E 90-A d NU M B E R 12 d D E C E M B E R 2008
VE N O U S TH R O M B O E M B O L I C DI S E A S E A F T E R
TO TA L HI P A N D KN E E AR T H R O P L A S T Y
used for all eligible patients50. Data on
wound drainage, symptomatic deep
venous thrombosis and pulmonary
embolism, hospital readmission, injec-
tion site problems, heparin-induced
thrombocytopenia, and patient satis-
faction and compliance were collected
prospectively. Complete data were col-
lected on 290 consecutive patients
treated with total joint replacement. The
original study design called for more
than 2000 patients, but the study was
terminated prematurely because of a
concern about patient safety. The results
were compared with those from the
previous study59. Major complications
occurred in 9%; symptomatic deep
venous thrombosis, in 7%; pulmonary
embolism, in 1.6%; hematoma and a
reoperation, in 2.3%; local wound
problems, in 6.2%; and heparin-
induced thrombocytopenia, in 0.8%.
The rate of major complications was
significantly higher and the efficacy was
significantly lower than those with the
non-ACCP protocol utilized immedi-
ately prior to the institution of this
study (Table I). In addition, the rate of
minor complications, including pro-
longed hospitalization, was 7%.
Complications associated with the
use of more aggressive protocols for
prophylaxis against deep venous
thrombosis have recently been reported
at other centers. Patel et al. reported
prolonged wound drainage and subse-
quent associated complications follow-
ing primary hip and knee replacement60.
The proportion of patients who still had
wound drainage on the fifth postoper-
ative day was significantly higher in their
group that received low-molecular-
weight heparin than it was in their
groups treated with the other studied
modalities (p = 0.003); each day of
prolonged wound drainage increased
the risk of wound infection by 42%
following a total hip arthroplasty and
by 29% following a total knee arthro-
plasty. Parvizi et al. studied the effect of
‘‘excessive anticoagulation’’ on the
subsequent prevalence of periprosthetic
infection61. For the patients in whom
infection developed following hip or
knee replacement, the factors that were
strongly associated with that complica-
tion were wound hematoma, wound
drainage, or an international normalized
ratio of >1.5 at the time of discharge.
Saleh et al. noted that implementation
of a protocol based on ACCP Grade-1A
recommendations led to a substantial
increase in the prevalence of com-
plications as compared with the rate
associated with a previously utilized
low-dose-Coumadin protocol62.
Fig. 1
Event rates of pulmonary embolism (PE) after total hip arthroplasty in the reviewed studies. Int dur’n = duration of intervention, F-up = duration of follow-
up, d/c = discharge, ASA = aspirin, and nd = no data.
2771
TH E J O U R N A L O F B O N E & JO I N T SU R G E RY d J B J S . O R G
VO LU M E 90-A d NU M B E R 12 d D E C E M B E R 2008
VE N O U S TH R O M B O E M B O L I C DI S E A S E A F T E R
TO TA L HI P A N D KN E E AR T H R O P L A S T Y
A number of orthopaedic studies
of less aggressive pharmacologic pro-
phylaxis for patients treated with hip or
knee replacement have demonstrated
excellent results when the end points
were death and symptomatic pulmo-
nary embolism. The largest body of data
relates to the use of lower-dose warfarin
protocols with a target international
normalized ratio of £2.0. Extremely low
prevalences of symptomatic pulmonary
embolism and death have been noted in
a number of studies from leading total
joint replacement centers over the past
fifteen years (Table II). Bern et al.
reported on more than 1000 patients
treated with total hip arthroplasty and
an ultra-low-dose warfarin protocol
consisting of 1 mg/day for seven days
prior to surgery, a variable dose with a
target international normalized ratio of
1.5 to 2 while the patient was in the
hospital, and 1 mg/day for four to six
weeks following discharge63. There were
only two cases of symptomatic deep
venous thrombosis and one nonfatal
pulmonary embolism, with a follow-up
rate of >99%.
The other deep venous thrombo-
sis prophylaxis regimen that has re-
ceived some support in the orthopaedic
literature is the use of aspirin. Although
there is an ACCP Grade-1A recom-
mendation against the use of aspirin
alone, Lotke and Lonner reported a
prevalence of pulmonary embolism of
only 0.06% after more than 3000 total
knee arthroplasties with aspirin pro-
phylaxis64. More recently, Callaghan
et al. reported no deaths after 427 total
knee arthroplasties, 73% of which were
low-risk procedures, in patients treated
with aspirin, foot pumps, and screening
ultrasound65. In a study of a large total
joint arthroplasty database of patients
treated with various prophylactic
modalities, including aspirin (4719),
warfarin (51,923), and low-molecular-
weight heparin or fondaparinux
(37,198), Bozic et al. reported no dif-
ference in mortality rates but substan-
tially less bleeding in the aspirin group66.
Many arthroplasty surgeons dis-
agree with some of the major conclu-
sions and recommendations of the
ACCP guidelines. The two major issues
are the use of venographically proven
deep venous thrombosis as the end
point of prophylaxis against venous
thromboembolic disease and the mea-
sure of efficacy of prophylactic regi-
mens. These criteria generally favor
aggressive pharmacologic prophylaxis
and correlate poorly with the preva-
lences of death and symptomatic pul-
monary embolism following hip and
knee arthroplasties. Largely because of
this issue, the AAOS formed a task force
to recommend clinical guidelines spe-
cifically for prophylaxis against deep
venous thrombosis in patients treated
with lower-extremity total joint re-
Fig. 2
Pooled event rates of pulmonary embolism (PE), fatal pulmonary embolism (PE Death), and all deaths after total hip arthroplasty in the reviewed studies.
LMWH = low-molecular-weight heparin.
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placement. This task force chose pre-
vention of symptomatic pulmonary
embolism, rather than reduction in the
prevalence of deep venous thrombosis,
as the end point67. Use of this different
end point led to different recommen-
dations regarding appropriate regimens
for prophylaxis against deep venous
thrombosis. Probably the greatest dif-
ference of opinion, however, is over the
prevalence of complications related to
the use of aggressive pharmacologic
prophylaxis. Many orthopaedic sur-
geons have observed a higher prevalence
of prolonged wound drainage with the
use of the more aggressive anticoagula-
tion protocols. Pharmacologic prophy-
lactic protocols resulting in a high risk
of wound drainage have also been
associated with hematoma formation,
prolonged hospitalization, and other
complications that can compromise the
clinical result. The number of total joint
procedures is expected to increase dra-
matically in the immediate future68,
with the increase in knee arthroplasties
predicted to be much greater than that
in hip arthroplasties and the highest rate
of increase expected among younger
patients, who tend to be healthier and at
lower risk for deep venous thrombosis.
The use of aggressive pharmacologic
protocols on a routine basis, therefore,
may put an increasingly higher number
of patients with a low risk for deep
venous thrombosis at risk for compli-
cations from the prophylaxis; therefore,
it is less likely to be cost-effective. The
clinical success of less aggressive proto-
cols and the increasing number of
young, healthy patients who are under-
going hip and knee replacements seem
to indicate that selective use of these
aggressive pharmacologic protocols,
with an emphasis on identifying pa-
tients who are at risk and more judi-
cious utilization of aggressive
prophylaxis against deep venous
thrombosis, is prudent.
AAOS Clinical Guidelines
Orthopaedic surgeons have been af-
fected by the ACCP guidelines for the
prevention of deep venous thrombosis
in patients treated with total hip or knee
arthroplasty. Deep venous thrombosis
(generally asymptomatic, detected by
venography or ultrasonography) was
the primary outcome measure in the
development of these guidelines50. Be-
Fig. 3
Pooled event rates of major bleeding and death from bleeding after total hip arthroplasty in the reviewed studies. LMWH = low-molecular-weight heparin.
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cause of the differences among patients
found in randomized pharmaceutical
studies and in the general arthroplasty
population, many orthopaedists believe
that these guidelines have limited
relevance to ‘‘real-world’’ decision-
making58. These guidelines emphasize
prophylaxis with strong pharmacologic
agents and seem to underrate the risks
of bleeding and ignore other adverse
outcomes, such as infection and joint
stiffness, related to these agents58.
Symptomatic pulmonary embo-
lism is relatively rare after total hip and
knee arthroplasty. In the Scottish Reg-
istry, the ninety-day rate of fatal pul-
monary embolism was 0.22% after
44,785 total hip arthroplasties and
0.15% after 27,000 total knee arthro-
plasties69. In the United States, a study of
Medicare data showed a ninety-day rate
of nonfatal pulmonary embolism of
0.93% after 58,521 total hip arthro-
plasties70. A review of 222,684 total knee
arthroplasties in California revealed a
ninety-day rate of symptomatic pul-
monary embolism of 0.41%71. Despite
the introduction of the ACCP guide-
lines, there appears to have been no
change in the rate of symptomatic or
fatal pulmonary embolism over the past
ten to fifteen years69,72. One study of 290
patients who were treated with total hip
or knee arthroplasty and given a ten-day
course of low-molecular-weight heparin
(Lovenox) according to the ACCP
Grade-1A recommendation demon-
strated a 9% rate of major bleeding or
wound complications, including a 4.7%
rate of readmission59. Symptomatic deep
venous thrombosis still occurred in
3.8% of the patients, nonfatal symptom-
atic pulmonary embolism still occurred
in 1.3%, and heparin-induced thrombo-
cytopenia still occurred in 1.3%. These
results led the authors to recommend
against the use of the ACCP Grade-1A
guideline of administering low-molecular-
weight heparin for ten days59.
The AAOS formed a working
group in early 2006 to develop a new
consensus guideline for prophylaxis
against symptomatic pulmonary embo-
lism after total hip and knee arthroplasty.
The key goals were to determine the
event rates of symptomatic and fatal
pulmonary embolism associated with
several interventions (aspirin, low-
molecular-weight heparin, synthetic
pentasaccharides, and warfarin), the
adverse-event rates (bleeding or death)
associated with these interventions, and
the natural history without prophylaxis
(in a study of a minimum of 1000
patients). The working group was
composed of eight members from the
Fig. 4
Event rates of pulmonary embolism (PE) after total knee arthroplasty in the reviewed studies. Int dur’n= duration of intervention, F-up= duration of follow-
up, ASA = aspirin, and nd = no data.
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AAOS (Norman A. Johanson, MD
[Chairman]; Paul F. Lachiewicz, MD; Jay
R. Lieberman, MD; Paul A. Lotke, MD;
Javad Parvizi, MD; Vincent Pellegrini,
MD; Theodore A. Stringer, MD; and
Paul Tornetta III, MD), and this group
consulted an evidence-review team from
the Center for Clinical Evidence Syn-
thesis at Tufts-New England Medical
Center (May Adra, PharmD; Ethan Balk,
MD, MPH; Stanley Ip, MD; Gowri
Raman, MD; and Joseph Lau, MD). The
working-group consensus decision was
to critically review the literature that met
the following criteria: a prospective
study of total hip or knee arthroplasties
performed since 1996 only, a cohort
study with at least 100 patients per
group, or a randomized controlled trial
with at least ten patients per treatment.
The evidence-review team found no
recent study on the natural history
(without prophylaxis) that included at
least 1000 patients. The literature review
included 2713 citations from MEDLINE
and Cochrane search engines and ten
other recent citations that the working
group was aware of but had not been
retrieved by the MEDLINE and Co-
chrane search engines. Of these 2723
citations, only forty-two articles met the
working-group criteria. There were
twenty-six articles with cohorts totaling
16,304 total hip arthroplasties and six-
teen articles with cohorts totaling 11,665
total knee arthroplasties. As was the case
in the development of the previous
AAOS knee osteoarthritis guidelines, the
individual studies were graded according
to levels of evidence (Table III). The
strength of each guideline recommen-
dation was graded on the basis of the
quality of the collection of studies from
which the recommendation was derived
(Table IV).
Since the event rates in most
studies were <1% and were not
normally distributed, a formal meta-
analysis was precluded. Statistical
methods included simple pooling (total
events/total patients) with calculations
of standard deviations, analyses of me-
dians among three or more cohorts,
random-effects-model meta-analysis of
logit transformed data73, and Bayesian
meta-analysis of proportions.
The Tufts evidence-review team
reported that one of the reviewed
studies was of good quality, twenty-four
were of fair quality, and seventeen were
of poor quality. The findings of only two
studies, in which patients with a history
of thromboembolism or bleeding were
not excluded, had a wide application.
The outcomes, with regard to pulmo-
nary embolism, of twenty-two studies
had moderate application. The out-
comes of eighteen studies had only
narrow application because of a short
follow-up. The reviewed studies were
heterogeneous in terms of follow-up
time, doses, intensity and timing of
Fig. 5
Pooled event rates of pulmonary embolism (PE), fatal pulmonary embolism (PE Death), and all deaths after total knee arthroplasty in the reviewed
studies. LMWH = low-molecular-weight heparin.
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interventions, cotreatments, eligibility
criteria, and surgical and anesthetic
techniques. In addition, the authors of
only three studies reported no support
from commercial funding.
The results of the literature review
are presented as separate forest plots for
hip and knee arthroplasty. These in-
clude plots for pulmonary embolism
after total hip arthroplasty (Fig. 1);
pulmonary embolism, fatal pulmonary
embolism, and all deaths after total hip
arthroplasty (Fig. 2); major bleeding
and death from bleeding after total
hip arthroplasty (Fig. 3); pulmonary
embolism after total knee arthroplasty
(Fig. 4); pulmonary embolism, fatal
pulmonary embolism, and all deaths
after total knee arthroplasty (Fig. 5);
and major bleeding and death from
bleeding after total knee arthroplasty
(Fig. 6). Several conclusions were de-
rived from the literature review. The
rate of asymptomatic pulmonary em-
bolism was approximately one per 300
arthroplasties with prophylactic treat-
ment. The rate of fatal pulmonary
embolism was approximately one per
1700 arthroplasties, and there was no
difference among prophylactic treat-
ments. The rate of death from bleeding
was approximately one per 3000 ar-
throplasties. Major bleeding complica-
tions were more common in patients
treated with systemic pharmacologic
prophylaxis (random effects model
summary estimate, 1.8%; 95% confi-
dence interval, 1.4% to 2.5%) than in
those treated with mechanical prophy-
laxis and aspirin (random effects model
summary estimate, 0.14%; 95% confi-
dence interval, 0.03% to 0.8%). There
were numerous limitations of the liter-
ature review and the analysis process.
There was a large amount of clinical
heterogeneity. Pulmonary embolism
was not the primary outcome in any
study, and the reporting of pulmonary
embolism was vague in many studies. As
the sample sizes in most of the studies
were inadequate for estimation of event
rates, pooled averages were used to
estimate the event rates. The working
group restricted the literature review to
studies in which the arthroplasties had
been performed since 1996, so many
older studies were excluded from analysis.
The consensus among the working group
was that surgical techniques and postop-
erative care have changed greatly since
Fig. 6
Pooledevent ratesofmajor bleedinganddeath frombleedingafter total kneearthroplasty in the reviewedstudies. LMWH= low-molecular-weight heparin.
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1996. There were very wide confidence
intervals for all of the interventions.
The AAOS guideline recommen-
dations derived from the working-
group consensus process included
preoperative evaluation of all patients by
the orthopaedic surgeon to assess the
risk of pulmonary embolism and the
risk of bleeding complications. It was
also recommended that the patient and
surgeon consider, in consultation with
the anesthesiologist, the use of regional
anesthesia41,45,74-77 and that the surgeon
consider using mechanical prophylaxis
intraoperatively or immediately post-
operatively with continuation until dis-
charge (Table V)14,30,41,64,74,78. The AAOS
guideline recommendations regarding
postoperative medication, based on the
literature review and analysis, stratify
the choices on the basis of the risks of
pulmonary embolism and major
bleeding complications (Table VI).
Overview
This critical literature review and anal-
ysis demonstrated no differences, in
terms of the total pulmonary embolism
rate, rate of fatal pulmonary embolism,
total death rate, or rate of death from
bleeding, among the different throm-
boembolism prophylaxis interventions.
The prevalence of major bleeding asso-
ciated with the combined intervention of
mechanical prophylaxis and aspirin was
very low compared with the prevalences
associated with the other interventions.
Orthopaedic surgeons should carefully
evaluate and document preoperatively
each patient’s specific risks for pulmo-
nary embolism and major bleeding.
Patients with previous symptomatic
pulmonary embolism, heritable throm-
bophilia, or a hypercoagulable state, and
those who will not be capable of rapid
mobilization, are usually mentioned as
examples of those who are at elevated
risk for pulmonary embolism. When
performing a total hip or knee arthro-
plasty procedure that could entail ex-
cessive bleeding (e.g., a revision
arthroplasty or a complicated primary
arthroplasty) or treating a patient who is
at higher risk for bleeding in other
locations (e.g., one with a history of a
bleeding disorder, recent gastrointestinal





Assess all patients preoperatively to determine
whether risk of pulmonary embolism is standard or high
III/B
Assess all patients preoperatively to determine whether
risk of bleeding complications is standard or high
III/C
Consider use of vena cava filter in patients who
have contraindications to anticoagulation
V/C
Consider intraoperative and/or immediate postoperative
mechanical compression
III/B
Consider regional anesthesia for the procedure
(in consultation with anesthesiologist)
IV/C
Consider continued use of mechanical prophylaxis
postoperatively
IV/C
Rapid patient mobilization V/C
Routine screening for thromboembolism is not
recommended
III/B
Educate patient about symptoms of thromboembolism
after discharge
V/B
*See Tables III and IV.




Standard risk of pulmonary embolism
and major bleeding
Aspirin, low-molecular-weight heparin, pentasaccharide,
warfarin (international normalized ratio £2)
III/B (C for dosing and timing)
Elevated risk of pulmonary embolism;
standard risk of bleeding
Low-molecular-weight heparin, pentasaccharide,
warfarin (international normalized ratio £2)
III/B (C for dosing and timing)
Standard risk of pulmonary embolism;
elevated risk of bleeding
Aspirin, warfarin (international normalized
ratio £2), no prophylaxis
III/C
Elevated risk of pulmonary embolism
and bleeding
Aspirin, warfarin (international normalized
ratio £2), no prophylaxis
III/C
*The agents in each row are given in alphabetical order.†See Tables III and IV.
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bleeding, or recent hemorrhagic stroke),
the orthopaedic surgeon should care-
fully consider the overall risk-benefit
ratio before proceeding with any specific
pharmacologic intervention. The AAOS
working group encourages the future
performance of prospective, random-
ized multicenter studies comparing the
various interventions that we men-
tioned, as well as new agents, with use of
symptomatic pulmonary embolism and
major bleeding that may affect the
patient’s outcome as clinical end points.
NOTE: The authors acknowledge Sarah Walcott-Sapp, research
assistant to Dr. Geoffrey Westrich at The Hospital for Special
Surgery, for her assistance in the preparation of this
manuscript.
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